Home » Market News » DirectorsTalk Highlights » Little-known Irish pharma firm among best performing on stock exchange on Covid-19 work
Open Orphan plc

Little-known Irish pharma firm among best performing on stock exchange on Covid-19 work

A little known Irish pharma firm, Open Orphan, is among the best performers on the Irish Stock Exchange this year after tapping millions of euro in contracts from the British government and other institutions to put together and advise on human clinical trials used in testing Covid-19 vaccines, the Irish Examiner can reveal.  

Its shares have climbed over 340% since the middle of January, and have risen 65% in the last month, to value the firm on Thursday at €167m, according to data from Euronext Dublin.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).